New Alzheimer’s Drug “Sola” Shows Promise
In her latest blog, Carillon’s Alzheimer’s care expert, Mary Ann Drummond, writes of a promising development from drug maker Eli Lilly.
A new drug in phase three testing from Eli Lilly called Solanezumab has all medical eyes watching closely. “Sola” as it has been nicknamed has shown great promise in test groups with a 34% success rate of slowing the disease process, something that no other medication to date has been able to do. Even better, it is believed that Sola may be able to delay the onset of Alzheimer’s for certain individuals. Unlike other medications used in the treatment of Alzheimer’s which currently focus on helping the brain to function at it’s best, Sola is a humanoid monoclonal antibody that binds with the amyloid peptides and acts as a neuro protector. While there is still much testing to be done before we will know if Sola will make it into our loved one’s treatment plans in the near future, it is exciting to hear of the current breakthrough. To read more, visit /pdl.com/technology-products/product-pipeline/Solanezumab/
Posted in Alzheimer's and Dementia Care, Perspectives on Alzheimer's, Sage Stories on August 14, 2015